{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:18:40Z","timestamp":1790421520990,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2242,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH-092443"],"award-info":[{"award-number":["MH-092443"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH-105660"],"award-info":[{"award-number":["MH-105660"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA-040127"],"award-info":[{"award-number":["DA-040127"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s13311-017-0552-9","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T12:54:01Z","timestamp":1498481641000},"page":"750-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Clozapine as a Model for Antipsychotic Development"],"prefix":"10.1016","volume":"14","author":[{"suffix":"Jr","given":"Frederick C.","family":"Nucifora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLOS Med"},{"issue":"10039","key":"10.1007\/s13311-017-0552-9_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1007\/s13311-017-0552-9_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.14074su1c.01","article-title":"Assessing cognitive impairment in patients with schizophrenia","volume":"77","author":"Schulz","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4 Suppl.","key":"10.1007\/s13311-017-0552-9_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1359786810385490","article-title":"Suicide and schizophrenia: a systematic review of rates and risk factors","volume":"24","author":"Hor","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","author":"Brown","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ajp.2012.12050599","article-title":"Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study","volume":"170","author":"Crump","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1007\/s13311-017-0552-9_bib10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-017-0552-9_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.07.001","article-title":"New therapeutic approaches for treatment-resistant schizophrenia: a look to the future","volume":"58","author":"Miyamoto","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","article-title":"A history of antipsychotic drug development","volume":"40","author":"Shen","year":"1999","journal-title":"Compr Psychiatry"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/01.pra.0000388628.44405.c0","article-title":"CNS drug development. Part I: the early period of CNS drugs","volume":"16","author":"Preskorn","year":"2010","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31887\/DCNS.2000.2.3\/ctamminga","article-title":"Treatment mechanisms: traditional and new antipsychotic drugs","volume":"2","author":"Tamminga","year":"2000","journal-title":"Dialogues Clin Neurosci"},{"issue":"11","key":"10.1007\/s13311-017-0552-9_bib17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine. A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1600-0447.1988.tb05164.x","article-title":"The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years","volume":"77","author":"Lindstrom","year":"1988","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr Bull"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"9896","key":"10.1007\/s13311-017-0552-9_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl. 3","key":"10.1007\/s13311-017-0552-9_bib25","first-page":"8","article-title":"Clozapine reduces violence and persistent aggression in schizophrenia","volume":"59","author":"Glazer","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 3","key":"10.1007\/s13311-017-0552-9_bib27","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1176\/appi.ajp.163.2.204","article-title":"Myocarditis during clozapine treatment","volume":"163","author":"Merrill","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"19","key":"10.1007\/s13311-017-0552-9_bib29","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2146\/ajhp070638","article-title":"Evaluating the association between clozapine and venous thromboembolism","volume":"65","author":"Paciullo","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.41.3.369","article-title":"Clozapine-related seizures","volume":"41","author":"Devinsky","year":"1991","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2045125311405566","article-title":"Clozapine-related EEG changes and seizures: dose and plasma-level relationships","volume":"1","author":"Varma","year":"2011","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br J Psychiatry"},{"issue":"33","key":"10.1007\/s13311-017-0552-9_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1192\/S0007125000297754","article-title":"Prolonged recovery in first-episode psychosis","volume":"172","author":"Edwards","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"issue":"10","key":"10.1007\/s13311-017-0552-9_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archpsyc.1997.01830220102017","article-title":"D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients","volume":"54","author":"Su","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R D"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4088\/JCP.10ac06470yel","article-title":"New antipsychotic drugs: how do their receptor-binding profiles compare?","volume":"71","author":"Richelson","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/13543784.17.1.61","article-title":"Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?","volume":"17","author":"Albers","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"10.1007\/s13311-017-0552-9_bib45","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eurpsy.2007.02.005","article-title":"Antipsychotic efficacy: relationship to optimal D2-receptor occupancy","volume":"22","author":"Pani","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib51","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib52","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2011.601738","article-title":"Serotonin 2A receptor antagonists for treatment of schizophrenia","volume":"20","author":"Ebdrup","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1472-8206.2000.tb00437.x","article-title":"Dopamine D4 receptors and development of newer antipsychotic drugs","volume":"14","author":"Kulkarni","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1081\/RRS-200032076","article-title":"Dopamine D4 receptors: beyond schizophrenia","volume":"24","author":"Tarazi","year":"2004","journal-title":"J Recept Signal Transduct Res"},{"issue":"7","key":"10.1007\/s13311-017-0552-9_bib55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(84)90068-4","article-title":"Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients","volume":"11","author":"Hommer","year":"1984","journal-title":"Psychiatry Res"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0893-133X(01)00249-4","article-title":"Guanfacine treatment of cognitive impairment in schizophrenia","volume":"25","author":"Friedman","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib58","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0552-9_bib59","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"10.1007\/s13311-017-0552-9_bib60","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2471-5","article-title":"Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo","volume":"220","author":"Humbert-Claude","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0b013e3182970490","article-title":"A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia","volume":"33","author":"Meskanen","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib63","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1060028017693029","article-title":"Pimavanserin: a novel antipsychotic for parkinson's disease psychosis","volume":"51","author":"Bozymski","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2-3","key":"10.1007\/s13311-017-0552-9_bib66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: comparison with reference dose risperidone, 6mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis","volume":"26","author":"Gressier","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1007\/s13311-017-0552-9_bib68","first-page":"117","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/YIC.0000000000000065","article-title":"Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review","volume":"31","author":"Krivoy","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"10.1007\/s13311-017-0552-9_bib70","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1517\/17425255.2015.1075003","article-title":"Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update","volume":"11","author":"Sriretnakumar","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00001756-199901180-00011","article-title":"No evidence for association of serotonin-2A receptor variant (102T\/C) with schizophrenia or clozapine response in a Chinese population","volume":"10","author":"Lin","year":"1999","journal-title":"Neuroreport"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib72","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","article-title":"Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response","volume":"32","author":"Lee","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-017-0552-9_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/0004563216686377","article-title":"Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms","author":"Akamine","year":"2017","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/tpj.2015.61","article-title":"Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population","volume":"16","author":"Xu","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","article-title":"Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response","volume":"32","author":"Arranz","year":"1998","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2013.736964","article-title":"Pharmacogenetics of antipsychotics: recent progress and methodological issues","volume":"9","author":"Zhang","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8979","key":"10.1007\/s13311-017-0552-9_bib78","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(95)92756-5","article-title":"Genetic variation of the 5-HT2A receptor and response to clozapine","volume":"346","author":"Nothen","year":"1995","journal-title":"Lancet"},{"issue":"8","key":"10.1007\/s13311-017-0552-9_bib79","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1176\/ajp.153.8.1092","article-title":"Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine","volume":"153","author":"Malhotra","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"9228","key":"10.1007\/s13311-017-0552-9_bib81","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0140-6736(05)74176-3","article-title":"Pharmacogenetics of the clozapine response","volume":"356","author":"Schumacher","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.09.003","article-title":"The environment and susceptibility to schizophrenia","volume":"93","author":"Brown","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib83","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/schbul\/sbt108","article-title":"Where GWAS and epidemiology meet: opportunities for the simultaneous study of genetic and environmental risk factors in schizophrenia","volume":"39","author":"McGrath","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-017-0552-9_bib84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nbd.2013.05.012","article-title":"Mouse models of gene-environment interactions in schizophrenia","volume":"57","author":"Kannan","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"7256","key":"10.1007\/s13311-017-0552-9_bib85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"Consortium","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1007\/s13311-017-0552-9_bib86","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1101\/gr.6665407","article-title":"Prediction of individual genetic risk to disease from genome-wide association studies","volume":"17","author":"Wray","year":"2007","journal-title":"Genome Res"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib87","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/bioinformatics\/btu848","article-title":"PRSice: Polygenic Risk Score software","volume":"31","author":"Euesden","year":"2015","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/19485565.2014.952705","article-title":"A polygenic risk score associated with measures of depressive symptoms among older adults","volume":"60","author":"Levine","year":"2014","journal-title":"Biodemography Soc Biol"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mp.2014.56","article-title":"Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients","volume":"20","author":"Frank","year":"2015","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib90","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach","volume":"3","author":"Ruderfer","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/JCP.0000000000000268","article-title":"Genetic overlap between antipsychotic response and susceptibility to schizophrenia","volume":"35","author":"Ikeda","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1017\/S0033291715001701","article-title":"Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia","volume":"46","author":"Martin","year":"2016","journal-title":"Psychol Med"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib93","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/mp.2012.67","article-title":"Genome-wide significant associations in schizophrenia to ITIH3\/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC","volume":"18","author":"Hamshere","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"2-3","key":"10.1007\/s13311-017-0552-9_bib94","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2016.06.032","article-title":"The role of the ITIH3 rs2535629 variant in antipsychotic response","volume":"176","author":"Brandl","year":"2016","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1007\/s13311-017-0552-9_bib96","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2008.40","article-title":"Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway","volume":"13","author":"Girgis","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"Suppl. 1","key":"10.1007\/s13311-017-0552-9_bib97","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"2-3","key":"10.1007\/s13311-017-0552-9_bib98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0920-9964(03)00180-4","article-title":"Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia?","volume":"67","author":"Gunnell","year":"2004","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2006.02.009","article-title":"Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction","volume":"84","author":"Zhao","year":"2006","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biopsych.2007.06.005","article-title":"AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families","volume":"63","author":"Thiselton","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib101","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.157.5.831","article-title":"Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients","volume":"157","author":"Kozlovsky","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"1-2","key":"10.1007\/s13311-017-0552-9_bib102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0920-9964(00)00174-2","article-title":"Low GSK-3 activity in frontal cortex of schizophrenic patients","volume":"52","author":"Kozlovsky","year":"2001","journal-title":"Schizophr Res"},{"issue":"2-3","key":"10.1007\/s13311-017-0552-9_bib103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3940(01)01688-3","article-title":"Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia","volume":"302","author":"Beasley","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-017-0552-9_bib104","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/ncomms5757","article-title":"Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles","volume":"5","author":"Goldstein","year":"2014","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-017-0552-9_bib105","article-title":"Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia","author":"Legge","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.274","article-title":"Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity","volume":"41","author":"Thorleifsson","year":"2009","journal-title":"Nat Genet"},{"issue":"9","key":"10.1007\/s13311-017-0552-9_bib107","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","article-title":"Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain","volume":"69","author":"Malhotra","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib108","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/tpj.2011.66","article-title":"Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene","volume":"13","author":"Chowdhury","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1007\/s13311-017-0552-9_bib109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/jnr.20208","article-title":"Microarray analysis of postmortem temporal cortex from patients with schizophrenia","volume":"77","author":"Aston","year":"2004","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bdi.12039","article-title":"Gene expression alterations in bipolar disorder postmortem brains","volume":"15","author":"Chen","year":"2013","journal-title":"Bipolar Disord"},{"issue":"2","key":"10.1007\/s13311-017-0552-9_bib111","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/hmg\/ddi022","article-title":"Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis","volume":"14","author":"Iwamoto","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1007\/s13311-017-0552-9_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003625","article-title":"Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum","volume":"3","author":"Mudge","year":"2008","journal-title":"PLOS ONE"},{"issue":"1-2","key":"10.1007\/s13311-017-0552-9_bib113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/01677063.2014.882918","article-title":"Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia","volume":"28","author":"Pietersen","year":"2014","journal-title":"J Neurogenet"},{"issue":"1-2","key":"10.1007\/s13311-017-0552-9_bib114","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/01677063.2013.878339","article-title":"Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia","volume":"28","author":"Pietersen","year":"2014","journal-title":"J Neurogenet"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/15622975.2010.530690","article-title":"Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study","volume":"12","author":"Schmitt","year":"2011","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"10.1007\/s13311-017-0552-9_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036351","article-title":"Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia","volume":"7","author":"Wu","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0552-9_bib117","article-title":"Analysis of differential gene expression mediated by clozapine in human postmortem brains","author":"Lee","year":"2016","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1007\/s13311-017-0552-9_bib118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","article-title":"Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A \u201ccentral hub\u201d in schizophrenia pathophysiology?","volume":"176","author":"Steullet","year":"2016","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1007\/s13311-017-0552-9_bib119","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1086\/507566","article-title":"Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene","volume":"79","author":"Tosic","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"30","key":"10.1007\/s13311-017-0552-9_bib120","doi-asserted-by":"crossref","first-page":"12165","DOI":"10.1073\/pnas.1206118109","article-title":"Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy","volume":"109","author":"Law","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1007\/s13311-017-0552-9_bib121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cge.12485","article-title":"Novel treatment strategies for schizophrenia from improved understanding of genetic risk","volume":"86","author":"Morris","year":"2014","journal-title":"Clin Genet"},{"issue":"11","key":"10.1007\/s13311-017-0552-9_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000235","article-title":"An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation","volume":"7","author":"Rosse","year":"2009","journal-title":"PLOS Biol"},{"issue":"7","key":"10.1007\/s13311-017-0552-9_bib123","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/mp.2011.123","article-title":"Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?","volume":"17","author":"Schubert","year":"2012","journal-title":"Mol Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0552-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0552-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0552-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:02:34Z","timestamp":1761807754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1878747923014538"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0552-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine as a Model for Antipsychotic Development","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0552-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}